Skip to content

Spinal Cord Stimulation (SCS) Dosing Study

Spinal Cord Stimulation (SCS) Dosing Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03284411
Enrollment
30
Registered
2017-09-15
Start date
2017-11-01
Completion date
2019-03-15
Last updated
2020-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Pain, Leg Pain

Brief summary

This study characterized the effects of amplitude on subject satisfaction and pain relief in subjects being treated by SCS.

Detailed description

This feasibility study assessed the following outcomes: * Patient satisfaction * VAS pain scores

Interventions

DEVICESpinal Cord Stimulation

Programming

Sponsors

MedtronicNeuro
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 22 years of age or older 2. Implanted with a RestoreSensor system (for back and leg pain) for at least 1 month 3. Has approproate SCS settings 4. Willing and able to provide signed and dated informed consent 5. Capable of comprehending and consenting in English 6. Capable of getting into the supine and sitting positions 7. Willing and able to comply with all study procedures and visits 8. On stable (no change in dose, route, or frequency) prescribed pain medications

Exclusion criteria

1. Implanted with leads for peripheral nerve stimulation or an implantable intrathecal drug delivery system 2. Had a pain-related surgery in the previous 1 month of enrollment or the intent to undergo surgery during the period of the study 3. Implanted with quadripolar lead 4. Currently enrolled or planning to enroll in a potentially confounding clinical study during the course of the study 5. Pregnant or is of child-bearing potential and unwilling to use a medically acceptable form of birth control during the study 6. Has untreated major psychiatric comorbidity 7. Has serious drug-related behavioral issues 8. Has unresolved major issues of secondary gain

Design outcomes

Primary

MeasureTime frameDescription
SCS Therapy Satisfaction8 weeksTo characterize the effect of four different amplitude settings on baseline SCS therapy satisfaction. At each follow-up visit, the following question was asked to measure satisfaction: Overall how satisfied or unsatisfied are you with this therapy?. The response choices were as follows: very satisfied, somewhat satisfied, neutral, somewhat unsatisfied, very unsatisfied. Each subject was considered to have maintained their baseline SCS therapy satisfaction if they selected the response very satisfied, somewhat satisfied, or neutral, otherwise they were considered dissatisfied with the therapy. The first visit in which each subject reported dissatisfaction of the therapy was recorded. The amplitude used during the prior visit was then considered to be the minimum amplitude that maintained each subject's therapy satisfaction. The frequency and percentage of subjects' that maintained baseline satisfaction were reported at each amplitude level.

Secondary

MeasureTime frameDescription
Number of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)8 weeksTo characterize the effect of four different amplitude settings on baseline pain relief. During each follow-up period the VAS pain score was recorded once a day, on a multi-day diary, where subjects rated their pain by making a vertical slash mark through the 0-10 cm line that best described their pain during the last 24 hours, with 0 = No pain and 10 = Worst pain imaginable. The higher VAS pain score represented worse pain. The average VAS pain scores from the last 3 days of the diary prior to the scheduled visit was used for analysis. Each subject was considered to have maintained their baseline pain if there was less than a 2 point increase in their average pain score at the follow-up period. The amplitude used during the prior visit was then considered to be the minimum amplitude that maintained the subject's pain relief. The frequency and percentage of subjects' that maintained their average baseline VAS pain score were reported at each amplitude level.

Countries

United States

Participant flow

Participants by arm

ArmCount
Spinal Cord Stimulation
Each subject was programmed to 4 different amplitude settings (80, 60, 40, and 20 percent of their perception threshold). Spinal Cord Stimulation: Programming
30
Total30

Baseline characteristics

CharacteristicSpinal Cord Stimulation
Age, Continuous65.1 years
STANDARD_DEVIATION 11.9
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
30 Participants
Region of Enrollment
United States
30 participants
Sex: Female, Male
Female
23 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 30
other
Total, other adverse events
5 / 30
serious
Total, serious adverse events
0 / 30

Outcome results

Primary

SCS Therapy Satisfaction

To characterize the effect of four different amplitude settings on baseline SCS therapy satisfaction. At each follow-up visit, the following question was asked to measure satisfaction: Overall how satisfied or unsatisfied are you with this therapy?. The response choices were as follows: very satisfied, somewhat satisfied, neutral, somewhat unsatisfied, very unsatisfied. Each subject was considered to have maintained their baseline SCS therapy satisfaction if they selected the response very satisfied, somewhat satisfied, or neutral, otherwise they were considered dissatisfied with the therapy. The first visit in which each subject reported dissatisfaction of the therapy was recorded. The amplitude used during the prior visit was then considered to be the minimum amplitude that maintained each subject's therapy satisfaction. The frequency and percentage of subjects' that maintained baseline satisfaction were reported at each amplitude level.

Time frame: 8 weeks

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Spinal Cord StimulationSCS Therapy Satisfaction60% perception threshold1 Participants
Spinal Cord StimulationSCS Therapy Satisfaction40% perception threshold0 Participants
Spinal Cord StimulationSCS Therapy SatisfactionBaseline6 Participants
Spinal Cord StimulationSCS Therapy Satisfaction80% perception threshold2 Participants
Spinal Cord StimulationSCS Therapy Satisfaction20% perception threshold21 Participants
Secondary

Number of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)

To characterize the effect of four different amplitude settings on baseline pain relief. During each follow-up period the VAS pain score was recorded once a day, on a multi-day diary, where subjects rated their pain by making a vertical slash mark through the 0-10 cm line that best described their pain during the last 24 hours, with 0 = No pain and 10 = Worst pain imaginable. The higher VAS pain score represented worse pain. The average VAS pain scores from the last 3 days of the diary prior to the scheduled visit was used for analysis. Each subject was considered to have maintained their baseline pain if there was less than a 2 point increase in their average pain score at the follow-up period. The amplitude used during the prior visit was then considered to be the minimum amplitude that maintained the subject's pain relief. The frequency and percentage of subjects' that maintained their average baseline VAS pain score were reported at each amplitude level.

Time frame: 8 weeks

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Spinal Cord StimulationNumber of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)Baseline5 Participants
Spinal Cord StimulationNumber of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)80% perception threshold3 Participants
Spinal Cord StimulationNumber of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)60% perception threshold1 Participants
Spinal Cord StimulationNumber of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)40% perception threshold2 Participants
Spinal Cord StimulationNumber of Participants Maintaining Baseline Pain as Measured on the Visual Analog Scale (VAS)20% perception threshold19 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026